Neuberg Diagnostics Targets ₹4,000-Cr IPO by FY28, Seeks Pre-IPO Funding to Accelerate Acquisition Strategy.

The Indian diagnostics sector is on the cusp of significant transformation, with Neuberg Diagnostics planning a monumental IPO slated between April and September of FY28. Aiming to raise between INR 3,500 crore and INR 4,000 crore, the company, founded by GSK Velu—who previously exited Metropolis Healthcare—has deployed a robust pre-IPO strategy focused on growth through acquisitions. Neuberg has recently secured a majority stake in NM Medical in Mumbai and is in discussions to obtain a majority stake in Mahajan Imaging & Labs in Delhi, reinforcing its position in key markets.

Market sentiment around Neuberg’s IPO is expected to be favorable due to its strategic acquisitions and solid financial performance. The company has reported a significant jump in revenue, from INR 464 crore for FY25 to an impressive INR 1,400 crore in FY26, underscoring its effective roll-up strategy. Additionally, the ongoing pre-IPO funding round that aims to secure INR 500 crore further instills confidence among investors, as it aims to expedite these acquisitions, thereby enhancing its operational scale ahead of the public offering.

For Indian investors, Neuberg’s upcoming IPO represents a unique opportunity to tap into a rapidly consolidating sector that is pivotal to healthcare in India. As the company aims to become the second-largest player in the diagnostics field, stakes in Neuberg could offer promising returns given the ongoing competitive landscape where firms are increasingly focused on innovation and growth. Thus, this IPO not only signifies Neuberg’s robust business model but also highlights the potential for lucrative investment outcomes in the burgeoning Indian diagnostics market.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)